The goal of this research is to examine the ability of Gallium-68 (68Ga) Prostate-Specific
Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to
detect sites of recurrent prostate cancer in patients with biochemical recurrence previously
treated with radical prostatectomy (RP) or external beam radiation (EBRT) and to assess
treatment response to subsequent salvage therapy.